Ads
related to: stage 4 lymphoma survival rate- Patient Characteristics
See Which Patient Types Are Fit
For This FDA-Approved Treatment
- Register for Updates
Stay Informed About The Latest
Clinical Data Updates & More
- View Dosing Information
Access The Dosing Schedule
& Administration Info
- Important Safety Info
Review Important Safety Info
On Our Official HCP Website
- Patient Characteristics
Search results
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial
MedPage Today· 6 days agoReplacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Zacks via Yahoo Finance· 2 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 3 days agoAt a median follow-up of 9.4 months, Krazati demonstrated a statistically significant and clinically...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 6 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 3 days agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with...
The Pendulum· 5 days agoKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days ago-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 ...
Understanding CAR T-cell therapy: A conversation with Northside’s Dr. Melhem Solh - Atlanta Business...
The Business Journals· 3 days agoDr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers...
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 4 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...
